Replimune Group (NASDAQ:REPL) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Replimune Group (NASDAQ:REPL) posted its earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07, Zacks reports.

Replimune Group Price Performance

NASDAQ REPL traded down $0.24 on Wednesday, reaching $11.95. 129,942 shares of the stock traded hands, compared to its average volume of 1,036,219. The firm’s fifty day simple moving average is $11.42 and its 200 day simple moving average is $9.49. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The company has a market cap of $816.42 million, a price-to-earnings ratio of -3.91 and a beta of 1.19. Replimune Group has a 12 month low of $4.92 and a 12 month high of $12.97.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the transaction, the chief financial officer now directly owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

REPL has been the topic of several analyst reports. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price on the stock. JPMorgan Chase & Co. raised their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research report on Tuesday. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Replimune Group has a consensus rating of “Buy” and a consensus price target of $16.80.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.